Virogin Biotech Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
170
- Latest Deal Type
-
2ndary - Private
- Investors
-
16
Virogin Biotech General Information
Description
Developer of oncolytic virus technology designed to treat tumors and inhibit tumor growth. The company's technology uses immunological principles and methods to research anticancer and antitumor immunity by capitalizing on a robust, transient antiviral immune response through synergy with multiple payload expressions, enabling patients to receive drugs that enhance systemic antitumor immunity.
Contact Information
Website
www.virogin.comCorporate Office
- 150-13511 Commerce Parkway
- Richmond, British Columbia V6V 2J8
- Canada
Corporate Office
- 150-13511 Commerce Parkway
- Richmond, British Columbia V6V 2J8
- Canada
Virogin Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Jun-2026 | Completed | Clinical Trials - Phase 3 | |||
| 8. Later Stage VC (Series D2) | 24-Sep-2021 | Completed | Clinical Trials - Phase 3 | |||
| 7. Later Stage VC (Series D1) | 07-May-2021 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC (Series C) | 21-Sep-2020 | Completed | Clinical Trials - Phase 3 | |||
| 5. Early Stage VC (Series B2) | 04-Dec-2018 | Completed | Clinical Trials - Phase 3 | |||
| 4. Early Stage VC (Series A2) | 28-Feb-2017 | Completed | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series A1) | 16-Mar-2016 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 01-Aug-2015 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Virogin Biotech Comparisons
Industry
Financing
Details
Virogin Biotech Competitors (70)
One of Virogin Biotech’s 70 competitors is TILT Biotherapeutics, a Venture Capital-Backed company based in Helsinki, Finland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TILT Biotherapeutics | Venture Capital-Backed | Helsinki, Finland | ||||
| Navrogen | Venture Capital-Backed | Cheyney, PA | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Amal Therapeutics | Formerly VC-backed | Geneva, Switzerland | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA |
Virogin Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Virogin Biotech Patents
Virogin Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026219131-A1 | Pharmaceutical combination containing bispecific antibody and oncolytic virus, and use thereof | Pending | 14-Apr-2025 | ||
| WO-2026103877-A1 | Lipid compound and lipid nanoparticle composition | Pending | 15-Nov-2024 | ||
| WO-2025222396-A1 | Oncolytic viral therapy for treating and preventing human papillomavirus (hpv) -associated malignancies | Pending | 24-Apr-2024 | ||
| WO-2025129693-A1 | Recombinant oncolytic herpes virus having an oxygen dependent degradation domain | Inactive | 22-Dec-2023 | ||
| WO-2025016031-A1 | Self-amplifying nucleic acid molecule and use thereof | Inactive | 19-Jul-2023 | A61P35/00 |
Virogin Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Virogin Biotech Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BlackPine Group | Venture Capital | Minority | ||
| China Life Private Equity | PE/Buyout | Minority | ||
| China Securities | Investment Bank | Minority | ||
| CS Capital (Beijing) | Growth/Expansion | Minority | ||
| GF Qianhe | Venture Capital | Minority |
Virogin Biotech Investments (2)
Virogin Biotech’s most recent deal was a Joint Venture with Sino Biotech. The deal was made on 14-May-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sino Biotech | 14-May-2019 | Joint Venture | Biotechnology | ||
| JV (Virogin Biotech and China National Biotec Group) | 08-May-2019 | Joint Venture | Other Pharmaceuticals and Biotechnology |
Virogin Biotech FAQs
-
When was Virogin Biotech founded?
Virogin Biotech was founded in 2015.
-
Where is Virogin Biotech headquartered?
Virogin Biotech is headquartered in Richmond, Canada.
-
What is the size of Virogin Biotech?
Virogin Biotech has 170 total employees.
-
What industry is Virogin Biotech in?
Virogin Biotech’s primary industry is Drug Discovery.
-
Is Virogin Biotech a private or public company?
Virogin Biotech is a Private company.
-
What is Virogin Biotech’s current revenue?
The current revenue for Virogin Biotech is .
-
How much funding has Virogin Biotech raised over time?
Virogin Biotech has raised $301M.
-
Who are Virogin Biotech’s investors?
BlackPine Group, China Life Private Equity, China Securities, CS Capital (Beijing), and GF Qianhe are 5 of 16 investors who have invested in Virogin Biotech.
-
Who are Virogin Biotech’s competitors?
TILT Biotherapeutics, Navrogen, AnTolRx, Amal Therapeutics, and Aro Biotherapeutics are some of the 70 competitors of Virogin Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
